-
July 18, 2008
Bone drug has benefits in cancer patients
NEW YORK (Reuters Health) - The bone-strengthening drug zoledronic acid not only reduces fracture risk in patients with cancer that has spread to the bones, it also improves overall survival, according to the results of a retrospective analysis of three large studies.
-
July 3, 2008
Doctors extract cancer cells from blood sample
BOSTON (Reuters) - An experimental process that snags lung cancer cells from a blood sample could give doctors real-time feedback on the most effective therapy, researchers reported on Wednesday.
-
June 2, 2008
Erbitux adds 5 weeks to lung cancer survival
CHICAGO (Reuters) - Lung cancer patients treated in a large clinical trial with ImClone Systems Inc's Erbitux and chemotherapy lived about five weeks longer than patients treated with chemotherapy alone, according to study results released on Saturday.
-
May 16, 2008
Lung cancer patients may live longer with Alimta
WASHINGTON (Reuters Life!) - Adding a little extra chemotherapy after finishing the initial course helped advanced lung cancer patients live longer without having their tumors grow or come back, researchers reported on Thursday.
-
March 13, 2008
Study shows way to predict lung cancer recurrence
WASHINGTON (Reuters) - It may be possible to predict whose lung cancer is likely to come back after surgery has apparently cured it, U.S. researchers reported on Wednesday.
-
February 27, 2008
Experimental lung cancer drug fails clinical trial
LONDON (Reuters) - AstraZeneca Plc is stopping a clinical trial of Recentin as a treatment for lung cancer after a mid-stage study failed to meet its main goal, although trials in colorectal cancer will move ahead.
-
February 18, 2008
Bayer stops late-stage Nexavar trial
BANGALORE (Reuters) - Bayer HealthCare, a U.S. based unit of Bayer AG, said it stopped a late-stage trial of Nexavar in patients with non-small cell lung cancer, after an independent data monitoring committee concluded that the study would not meet its main goal of improved overall survival.
-
January 30, 2008
Nexavar shows promise in acute myeloid leukemia
CHICAGO (Reuters) - The kidney cancer pill Nexava, know generically as sorafenib, has shown promise in treating a small number of people with a type of blood cancer known as acute myeloid leukemia, or AML, U.S. researchers said on Tuesday.
-
January 30, 2008
Lung cancer surgery improves quality of life
NEW YORK (Reuters Health) - Surgery for lung cancer can have a substantial impact on long-term, health-related quality of life, the results of a study published in the current issue of the Journal of Clinical Oncology suggest.
-
January 22, 2008
Nexavar significantly boosts hypertension risk: study
LONDON (Reuters) - Bayer AG and Onyx Pharmaceutical Inc.'s key cancer drug Nexavar significantly raises the risk of high blood pressure, U.S. researchers said on Tuesday.
-
November 27, 2007
PET scans can help lung cancer diagnosis - study
WASHINGTON (Reuters) - The use of positron emission tomography, known as PET scans, can improve the diagnosis of people with lung cancer and better guide treatment decisions, Canadian researchers said on Tuesday.
-
September 5, 2007
Antisoma says lung cancer drug improves survival
LONDON (Reuters) - British cancer specialist Antisoma said on Wednesday that an intermediate phase II clinical trial confirmed that its biggest drug hope, ASA404, could help lung cancer patients to live for longer.
-
August 31, 2007
AIDS drug shows potential as weapon against cancer
WASHINGTON (Reuters) - A drug used to treat people infected with the AIDS virus has shown promise as a possible future weapon against cancer, U.S. researchers said on Friday.
-
August 24, 2007
EU approves Avastin for lung cancer: Roche
ZURICH (Reuters) - The European Union has approved Avastin (Roche Holding AG) to treat patients with advanced non-small-cell lung cancer, the Swiss drugmaker said on Friday.
-
August 22, 2007
UK's NICE upholds block on lung cancer drug
LONDON (Reuters) - Britain's healthcare cost-effectiveness watchdog said on Wednesday that pemetrexed, sold by Eli Lilly and Co. under the trade name Alimta, would not be recommended as a treatment for lung cancer on the state health service.
-
July 26, 2007
Added chemotherapy improves lung cancer survival
NEW YORK (Reuters Health) - A course of chemotherapy prior to standard treatment, known as "induction" chemotherapy, appears to improve survival in patients with advanced non-small-cell lung cancer (NSCLC), the most common type of lung cancer, according to a report in the International Journal of Radiation Oncology*Biology*Physics.
-
July 18, 2007
Lung cancer prognosis better for non-smokers
NEW YORK (Reuters Health) - Cigarette smokers who develop non-small-cell lung cancer, the most common type of lung cancer, have a less favorable outlook than do their counterparts who have never smoked, researchers report in the July issue of Chest.
-
July 13, 2007
New breath test detects lung cancer
NEW YORK (Reuters Health) - Testing exhaled breath with a small sensor array can detect lung cancer with moderate accuracy, researchers report.
-
June 4, 2007
Shark cartilage of no benefit to in lung cancer
CHICAGO (Reuters Health) - The addition of the shark cartilage extract "Neovastat" to standard chemotherapy and radiation does not improve survival in patients with non-small-cell lung cancer (NSCLC), according to results of a large multicenter study reported Saturday at the 43rd annual meeting of the American Society of Clinical Oncology.
-
June 4, 2007
Brain radiation increases lung cancer survival
CHICAGO (Reuters Health) - Preventive radiation to the brain significantly reduces the risk of lung cancer spreading to this organ and improves survival, according to data presented in a session Monday at the 43rd annual meeting of the American Society of Clinical Oncology.
-
March 9, 2007
UK's NICE rejects costly Roche lung cancer pill
LONDON (Reuters) - Roche's once-a-day lung cancer pill Tarceva is of limited use and too expensive to be given on the state health service, Britain's main cost-effectiveness watchdog said on Friday.